| abstract |
The present invention relates to a method for the commercial mass production of t-butyl (2,2-dimethyl-6-hydroxymethyl-[1,3]dioxane-4-yl) acetate having an optical activity, which is a core intermediate in the preparation of a variety of HMG-CoA reductase inhibitors, and to novel intermediates for the same. According to the preparation method of the present invention, t-butyl (2,2-dimethyl-6-hydroxymethyl-[1,3]dioxane-4-yl) acetate having an optical activity can be prepared in an economically advantageous and effective manner. |